The Changing Landscape of Medical Regulation and Research: From the FDA’s Leucovorin Pivot to NIH Funding Volatility
admin The landscape of American healthcare and biomedical research is currently undergoing a period of profound...
Health
After fight over cancer clinicians, Dana-Farber and Brigham are playing nice again
In a joint communication recently distributed to the thousands of clinicians and support staff who...
Navigating the Shifting Landscapes of American Healthcare: Policy Upheavals, Mental Health Consolidation, and Clinical Advances.
The landscape of American healthcare is currently undergoing a period of profound transformation, marked by...
Vertex says its drug successfully reduced marker of kidney disease in late-stage trial
The Phase 3 results focus on the reduction of proteinuria—the presence of excess proteins in...
The ER staffing conflict, and no facility fee for a marmot
However, while the headlines are dominated by the glamour of weight-loss breakthroughs, a much grittier...
The Self-Destruction of Vinay Prasad: A Reckoning for the FDA’s Most Polarizing Figure.
The announcement came late on a Friday evening, the traditional hour for news that an...
The FDA’s War of Words Over UniQure: A Senior Official’s Unusual Campaign Against a Huntington’s Treatment.
The atmosphere during the Food and Drug Administration’s media call this past Thursday was not...
Novo Nordisk’s Wegovy and Ozempic shots could be made for as little as $3 a month, analysis finds
After reviewing data for active pharmaceutical ingredients (API) from the past two years, the researchers...
Federal Autism Advisory Panel Cancels First Meeting Amid Scientific Backlash and Secretary Kennedy’s Controversial Appointments
The abrupt cancellation of the first scheduled meeting of the Interagency Autism Coordinating Committee (IACC)...
Vinay Prasad, key Makary ally and a focus of controversy at the FDA, is leaving the agency
Prasad’s tenure has been nothing short of transformative, albeit deeply divisive. As the head of...